The Psychedelic Pulse

Bianca Schnarr interviews founders of Penn Psychedelics Collaborative (PPC) Victor Pablo Acero, PhD & Taylor Andrews Flatt. PPC is a transdisciplinary research consortium at the University of Pennsylvania. Read the article to check it out! https://lnkd.in/gWRep_4r

This piece by Adam Miezio discusses how professional athletes are discovering benefits of psychedelic for brain health. Professionals in the field are advocating that "sports medicine practitioners should become aware of psychedelic agents and the developing field of research examining their role in the management of mental health and wellbeing." Follow The Psychedelic Pulse and subscribe to our free newsletter! Daniel Carcillo #mentalhealth #concussion @ https://lnkd.in/gB7P44Qj

Psilocybin significantly disrupts brain connectivity and the intensity of the psychedelic experience correlates with the intensity of beneficial effects. In this article, our #pharmacist breaks down another cool study that uses fMRI to look inside our brains! Check out the full article and subscribe to our free newsletter! https://lnkd.in/gMEWG-9i

Research show the strongest support for “mystical experience” and “ego dissolution” as acute experiences which mediate the therapeutic effects of psychedelic treatment. Our #pharmacist breaks down the paper comparing mechanism of action of #SSRIs vs #psilocybin. This paper by Brandon Weiss is a double blinded Phase 2 study. Compass Pathways's psilocybin formulation was used. https://lnkd.in/g-n9byRt

Many of you know that #FDA rejected approval MDMA-AT this week. What happens next is still in the air. Our guest writer explores what's in #mdma's future. Will the support of politicians & high profile supporters be enough? Read the article to read this fascinating point of view. Don't forget to subscribe to our free newsletter! And always hit that repost button :) #mentalhealth #ptsd #science https://lnkd.in/gQ3wNY-F

Interesting read by Dr. Emily Kulpa, PharmD

Gilgamesh Pharmaceuticals made waves earlier by announcing the AbbVie deal! Have you heard of them? In this issue of reviewing biopharmas with psychedelics compounds let's look at Gilgamesh Pharmaceuticals. They have 4 promising candidates in their pipeline: GM-1020: This is an oral NMDA receptor antagonist currently in Phase 2 trials. It is designed to offer rapid-acting antidepressant effects without the dissociative side effects typically associated with similar treatments. GM-1020 is being developed for potential at-home use, making it convenient for patients. GM-2505: Another exciting candidate, GM-2505, is a short-acting 5-HT2A agonist also in Phase 2 trials. It acts within 60-90 minutes, providing quick relief for depression and anxiety. This compound is designed to require less clinical supervision, potentially increasing patient access to treatment. GM-5022: In the IND enabling phase, this oral neuroplastogen aims to treat depression and anxiety without causing hallucinations. It represents a new class of treatments that could significantly improve patient outcomes. GM-3009: This is a safer ibogaine analog in pre-clinical development. They focus on treating opioid use disorder, PTSD, and traumatic brain injury, with improved cardiac safety and efficacy compared to traditional ibogaine. Ibogaine, a naturally occurring psychoactive substance, has shown promise in treating addiction, but its use has been limited due to significant cardiovascular risks. Gilgamesh’s analog aims to retain the therapeutic benefits while mitigating these risks, potentially offering a groundbreaking treatment for addiction and trauma-related disorders. If you enjoy reading this, please subscribe to our free weekly newsletter at The Psychedelic Pulse!

#Psychedelics like LSD and psilocybin might provide effective #pain relief and improve mood, with fewer side effects and lower addiction risks compared to #opioids. Repost & help get the word out. Help us spread science of mental health! Subscribe to our free weekly newsletter at The Psychedelic Pulse. https://lnkd.in/gVH8pkAR

Ketamine 101! In this issue, we cover some basics of #ketamine! Did you know that Ketamine, originally an anesthetic, is now being explored for treating severe depression and anxiety? In this issue, our pharmacist discusses its FDA status and insurance coverage in US. Sign up to our free newsletter today! Every week we drop bite size knowledge straight into you inbox. https://lnkd.in/gM_ya6Rs

This Op-ed by Mattha Busby generated a lot of conversations! What does the #psychedelic LinkedIn community think about it? Share your thoughts below! https://lnkd.in/gmY4bExu